Willumsen Johannes Sverre, Grytten Nina, Aarseth Jan, Myklebust Tor Åge, Myhr Kjell-Morten, Midgard Rune
Department of Neurology, Møre og Romsdal Hospital Trust, Molde, Norway
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.
J Neurol Neurosurg Psychiatry. 2022 Sep 12;93(11):1154-61. doi: 10.1136/jnnp-2022-329169.
Persons with multiple sclerosis (pwMS) have higher risk of mortality compared with the general population. Longitudinal studies are important for understanding the evolution of survival in pwMS.
Examine changes in mortality among pwMS during the past seven decades.
We followed pwMS from Hordaland and Møre and Romsdal in Western Norway, with disease onset from before 1950, identified from population-based epidemiological surveys and the Norwegian MS Registry and Biobank, until 1 January 2021. Data were linked to the Norwegian Cause of Death Registry to obtain underlying cause of death. We examined all-cause, and cause-specific mortality using standardised mortality ratios (SMR) and excess death rates (EDR). We calculated life expectancies and assessed survival stratified by sex, age and disease phenotype at onset. We compared hazard ratios (HRs) for mortality, in pwMS diagnosed before and after the era of disease-modifying treatment (DMT).
Of 3624 pwMS, 964 (55.5% women) had died, predominantly of multiple sclerosis (49.0%). Median life expectancy for pwMS was 74.3 years (95% CI 73.3 to 75.3), compared with 83.1 years for the general population (p<0.001). From disease onset, pwMS survived 14.6 years shorter than the general population (p<0.001). Overall, SMR was 2.3 (95% CI 2.13 to 2.42) and EDR was 6.8 (95% CI 6.42 to 7.09) for pwMS. Treatment-eligible pwMS diagnosed in the DMT era had the lowest risk of mortality, HR 0.49 (95% CI 0.34 to 0.70,p<0.001).
Excess mortality among pwMS declined during the past seven decades, possibly due to improved diagnostics, better symptomatic treatment and access to DMTs.
与普通人群相比,多发性硬化症患者(pwMS)的死亡风险更高。纵向研究对于了解pwMS患者生存率的演变很重要。
研究过去七十年来pwMS患者死亡率的变化。
我们追踪了挪威西部霍达兰郡、默勒-鲁姆斯达尔郡的pwMS患者,这些患者的疾病发病时间在1950年之前,通过基于人群的流行病学调查以及挪威多发性硬化症登记处和生物样本库确定,随访至2021年1月1日。数据与挪威死亡原因登记处相关联,以获取潜在死因。我们使用标准化死亡率(SMR)和超额死亡率(EDR)来研究全因死亡率和特定原因死亡率。我们计算了预期寿命,并按性别、年龄和发病时的疾病表型评估了生存率。我们比较了疾病修饰治疗(DMT)时代之前和之后诊断出的pwMS患者的死亡风险比(HR)。
在3624例pwMS患者中,964例(55.5%为女性)死亡,主要死因是多发性硬化症(49.0%)。pwMS患者的中位预期寿命为74.3岁(95%置信区间73.3至75.3),而普通人群为83.1岁(p<0.001)。从疾病发病起,pwMS患者的存活时间比普通人群短14.6年(p<0.001)。总体而言,pwMS患者的SMR为2.3(95%置信区间2.13至2.42),EDR为6.8(95%置信区间6.42至7.09)。在DMT时代诊断出的符合治疗条件的pwMS患者死亡风险最低,HR为0.49(95%置信区间0.34至0.70,p<0.001)。
在过去七十年中,pwMS患者的超额死亡率有所下降,这可能归因于诊断的改善、更好的对症治疗以及DMT的使用。